pbio.3002544.s008.pdf (40.9 kB)
pCEBS and SFC do not alter VP35 IFNβ antagonist activity.
journal contribution
posted on 2024-02-29, 18:53 authored by Carlos A. Rodríguez-Salazar, Sarah van Tol, Olivier Mailhot, Maria Gonzalez-Orozco, Gabriel T. Galdino, Abbey N. Warren, Natalia Teruel, Padmanava Behera, Kazi Sabrina Afreen, Lihong Zhang, Terry L. Juelich, Jennifer K. Smith, María Inés Zylber, Alexander N. Freiberg, Rafael J. Najmanovich, Maria I. Giraldo, Ricardo Rajsbaum(A) IFN-β promoter assay HEK293T cells were transfected with 100 ng of VP35 WT and treated for 24 h with 200 μm of pCEBS, SFC, or DMSO as vehicle. Then, cells were transfected with 3.125 μg/ml of HMW Poly I:C for 16 h. (B) Western blot analysis of (A). Data are depicted as mean + SEM. Two-Way ANOVA Tukey’s multiple comparisons tests. The data underlying the graphs shown in the figure can be found in S1 Data.
(PDF)
History
Usage metrics
Categories
Keywords
xlink "> ebolavirususing computational methodshighly pathogenic virusescompounds reduced replicationalso interact nonub interacting surfaceub ); howeverviral polymerase complexreduced vp35 associationinterferon antagonist vp35covalent interacting complexlinked polyub chainsebov replication requiresub interactions leadingdiminished polymerase activitypolymerase complexub nonregulating interactionsdiscovered compoundscovalent ubiquitinationvp35 interactsblock vp35usp5 ),unanchored polyububiquitin chainstested mutationspromising antipreviously showednovel rolemouse modelminigenome assayinfectious ebovectopic expression
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC